Spruce Biosciences, Inc. (SPRB) Stock

Spruce Biosciences, Inc. (SPRB) is a Healthcare stock trading at $52.21 (as of 2026-06-18), with a market capitalization of $141.11M and a trailing P/E of -0.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Spruce Biosciences, Inc. is a biopharmaceutical company developing and advancing therapies for rare endocrine disorders. Its lead program centers on tildacerfont for adult and pediatric congenital adrenal hyperplasia and for females with polycystic ovary syndrome, and it operates under a licensing agreement with Eli Lilly and Company for certain research, development, and commercialization activities.

Valuation — source: SEC EDGAR (first-party)
Price	$52.21
Market Cap	$141.11M
P/E Ratio	-0.9
EV / EBITDA	-2.8
Price / Book	4.07
DCF Value (model)	$-377.85
DCF Upside vs Price	-823.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$0.00
Return on Equity	-107.3%
Debt / Equity	0.19
Current Ratio	4.67
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	3840.3%

Financial Health — source: SEC EDGAR
Altman Z-Score	-4.87 (distress)

Valuation vs Sector & Industry
Stock P/E	-0.9
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-104.1%
vs Industry	-105.1%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	Ikarian Capital, LLC ($7.93M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Javier Szwarcberg
Employees	20
Country	US
IPO Date	2020-10-09

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.